New England Journal of Medicine· 2017Q1· Clinical trial
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- 6,031citations
- Q1SCImago
- 2017year
Short summary
In patients with cardiovascular disease already on statins, adding evolocumab significantly reduced major cardiovascular events by 15% compared to placebo, achieving LDL cholesterol levels as low as 30 mg/dL.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Surgery
SurgeryMedicine